Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — Merger or Acquisition (June 2007)
18 slides from Lexicon Pharmaceuticals's merger presentation, Jun 18, 2007
Slide 1: Building a Major Biopharmaceutical Company June 2007
Building a Major Biopharmaceutical Company June 2007
Slide 2: Forward-looking Statements
This presentation contains "forward-looking statements," including statements about Lexicon's plans for the development of and the timing of regulatory filings for its drug candidates and assessments of their therapeutic and commercial potential, drug discovery and research programs, growth and futu
Slide 3: Our Strategy
wy lexicon pharmaceutical Our Strategy
Slide 4: Building an Integrated Biopharmaceutical Company
Building an Integrated Biopharmaceutical Company Broad understanding of gene function without equal in the industry Over 100 new, selective and potent targets Extensive pipeline of new drug candidates World-class medicinal chemistry and antibody discovery capabilities Strength in clinical developmen
Slide 5: Lexicon Has Unique Insights into the Genome
Lexicon Has Unique Insights into the Genome Unparalleled understanding of "drug-able" gene function Large-scale evaluation of the medical potential of Genome5000 Approximately 4,100 genes evaluated to date Understanding drug action using gene knockouts has already resulted in over 100 novel, selecti
Slide 6: Lexicon Has an Extensive Pipeline of New Drugs
Lexicon Has an Extensive Pipeline of New Drugs Lexicon's 10 to 10 program is dedicated to bringing 10 new drug candidates into clinical trials through 2010 The Genome5000 discovery capabilities have fueled the evolution from a genetics platform to drug discovery and development Both small molecule a
Slide 7: Capabilities Validated by Established Alliances
Capabilities Validated by Established Alliances Biologic drug target alliance initiated at the end of 2002 and expanded at the end of 2005 to include biotherapeutic drug discovery and development Several promising candidates in preclinical research Alliance to discover, develop, and commercialize no
Slide 8: New Drug Discoveries are in Clinical Development
New Drug Discoveries are in Clinical Development Preclinical LX6171 - Alzheimer's/Cognition LX1031 - Irritable Bowel Syndrome LX1032 - Gastrointestinal Disorders LX2931 - Rheumatoid Arthritis LX2932 - Autoimmune disease LX4211 - Diabetes LX7101 - Glaucoma .... Phase 1 Phase 2 Phase 3 Corporate allia
Slide 9: Drug-Based Collaborations Will Play a Key Role, Yet Best Value Creation Requires Substantial Investment
Drug-Based Collaborations Will Play a Key Role, Yet Best Value Creation Requires Substantial Investment Collaborations and Alliances will help maximize the potential of extensive pipeline Our strategy is to select collaborators based on: Commitment to the project Relevant expertise/focus in therapeu
Slide 10: Overview of Invus and Symphony Transactions June 2007
Overview of Invus and Symphony Transactions June 2007
Slide 11: The Strategic Impact of These Transactions
The Strategic Impact of These Transactions Provide $265 million in financing (common stock with a significant premium built in) Front portion of our drug pipeline is approaching Phase 2 Corporate partnering strategy can be optimized for drug development success without short-term financing pressure
Slide 12: The Invus Transaction Represents a Significant Financial Commitment
The Invus Transaction Represents a Significant Financial Commitment At closing, Invus to purchase $205MM in common stock $51MM at $3.09 per share (10-day volume weighted average as of 6/14) $154MM at $4.50 per share, a 46% premium to 6/15 closing price Financing framework may provide up to cumulativ
Slide 13: Invus Overview
Invus Overview Invus is a 22 year-old equity investment firm with an impressive track record A strategy-focused, long-term investor Manages in excess of $4Bn of capital with investments in a broad range of industries Select investments have included: Keebler Foods Company Weight Watchers Internation
Slide 14: The Symphony Collaboration Will Further Advance our First Three Drug Candidates
The Symphony Collaboration Will Further Advance our First Three Drug Candidates Funding collaboration for the clinical development of LX1031, LX1032 and LX6171 through Phase 2 Symphony funds $60 million Lexicon licenses IP of programs to Symphony Icon, a newly formed company funded by Symphony Lexic
Slide 15: Symphony Overview
Symphony Overview Symphony manages $315 million in capital dedicated to investments in clinical development programs Alliance with RRD International brings significant clinical development resources Global regulatory, preclinical and clinical support for biotechnology and pharmaceutical companies Co
Slide 16: Process and Timing Going Forward
Process and Timing Going Forward Symphony Transaction closed on June 15, 2007 Invus Proxy expected to be distributed mid-summer Shareholder vote expected to take place in fiscal third quarter
Slide 17: Proxy Statement
Proxy Statement Lexicon will file a proxy statement and other documents with the Securities and Exchange Commission relating to the approval of the Invus transactions. Stockholders are urged to carefully read the proxy statement when it becomes available, because it will contain important informatio
Slide 18: Lexicon is Focused on Discovering and Developing Breakthrough Treatments for Human Disease
Lexicon is Focused on Discovering and Developing Breakthrough Treatments for Human Disease Selecting the best targets From Genetics to Drug Development Selecting the best therapeutics
Lexicon Pharmaceuticals — Merger or Acquisition (June 2007) on 6ix